Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Blood

Volumn 112, Issue 8, 2008, Pages 3330-3338

  Branford, Susan ^a   Fletcher, Linda ^a   Cross, Nicholas C P ^b   Müller, Martin C ^c   Hochhaus, Andreas ^c   Kim, Dong Wook ^d   Radich, Jerald P ^e   Saglio, Giuseppe ^f   Pane, Fabrizio ^g   Kamel Reid, Suzanne ^h   Wang, Y Lynn ⁱ   Press, Richard D ^j   Lynch, Kevin ^k   Rudzki, Zbigniew ^a   Goldman, John M ^l   Hughes, Timothy ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d The Catholic University of Korea   (South Korea)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k Novartis Pharmaceuticals Australia Ltd   (Australia)

^l HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; HUMAN; INTERNATIONAL STANDARD UNIT; LABORATORY TEST; PRIORITY JOURNAL; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; VALIDATION PROCESS; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; CLINICAL CHEMISTRY; CLINICAL TRIAL; CYTOGENETICS; GENETIC PROCEDURES; GENETICS; METABOLISM; METHODOLOGY; MULTICENTER STUDY; ONCOLOGY; REPRODUCIBILITY; STANDARD; TREATMENT OUTCOME;

CHEMISTRY, CLINICAL; CLINICAL TRIALS AS TOPIC; CYTOGENETICS; FUSION PROTEINS, BCR-ABL; GENETIC TECHNIQUES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICAL ONCOLOGY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 54049139246     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-150680     Document Type: Article

References (43)

1. Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;13:1825-1832.
2. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107:587-599.
3. Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood. 2001;98:1701-1707.
4. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. BrJ Haematol. 2002;118:771-777.
5. Kim YJ, Kim DW, Lee S, et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABLgene after hematopoietic stem cell transplantation in CML. Eur J Haematol. 2002;68:272-280.
6. Lee WI, Kantarjian H, Glassman A, Talpaz M, Lee MS. Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction. Ann Oncol. 2002;13:781-788.
7. Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia. 2003;17:2392-2400.
8. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.
9. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2404-2417.
10. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425-3432.
11. Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 2006;107:4250-4256.
12. lacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006;12:3037-3042.
13. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 2007;13:6136-6143.
14. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
15. Paschka P, Branford S, Lorentz C, Hehlmann R, Hughes T, Hochhaus A. Comparison of "log reduction from median pretherapeutic value" vs ratio Bcr-Abl/Abl to express the therapeutic response in CML [abstract]. Blood. 2004;104:287a.
16. Zhang T Grenier S, Nwachukwu B, et al. Interlaboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn. 2007; 9:421-430.
17. Robertson JS. International standardization of gene amplification technology. Biologicals. 1998; 26:111-113.
18. Cross NCP, Hughes TP, Hochhaus A, Goldman JM. International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leukemia Res. 2008;32:505-506.
19. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABLtranscripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
20. Branford S, Cross NCP, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABLtranscripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20:1925-1930.
21. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. In: Illand H, Hertzgerg M, Marlton P, eds. Myeloid Leukemia: Methods and Protocols. Methods in Molecular Medicine, vol. 125. Totowa, NJ: Humana Press:2006:69-92.
22. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia. 2003;17:2318-2357.
23. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reversetranscriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program. Leukemia. 2003;17:2474-2486.
24. Stock W, Yu D, Karrison T, et al. Quantitative realtime RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006;28:1099-1103.
25. Müller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22:96-102.
26. Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia. 2006;20:664-670.
27. Krouwer JS, Tholen DW, Garber CC, et al. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline-second edition. (NCCLS document EP9-A2.) Wayne, PA: Clinical and Laboratory Standards Institute, 2002.
28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
29. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Ftes. 1999;8:135-160.
30. Hughes TP, Branford S. Monitoring disease response. In: Melo JV, Goldman JM, eds. Myeloproliferative Disorders. Berlin: Springer-Verlag; 2007:143-164.
31. Bennett ST, Eckfeldt JH, Belcher JD, Connelly DP. Certification of cholesterol measurements by the National Reference Method Laboratory Network with routine clinical specimens: effects of network laboratory bias and imprecision. Clin Chem. 1992;38:651-657.
32. Hollis S. Analysis of method comparison studies. Ann Clin Biochem. 1996;33(Pt 1):1-4.
33. Cortes J, O'Brien S, Jabbour E, et al. Efficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood. 2007; 110:17a. Abstract 29.
34. Cortes J, O'Brien S, Jones D, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia in early chronic phase [abstract]. Blood. 2007:110:17a. Abstract 30.
35. Myers GL, Kimberly MM, Waymack PP, Smith SJ, Cooper GR, Sampson EJ. A reference method laboratory network for cholesterol: a model for standardization and improvement of clinical laboratory measurements. Clin Chem. 2000;46:1762-1772.
36. Baadenhuijsen H, Steigstra H, Cobbaert C, Kuypers A, Weykamp C, Jansen R. Commutability assessment of potential reference materials using a multicenter split-patient-sample betweenfield-methods (twin-study) design: study within the framework of the Dutch project "Calibration 2000." Clin Chem. 2002;48:1520-1525.
37. Petersen PH, de Verdier C-H, Groth T, Fraser CG, Blaabjerg O, Horder M. The influence of analytical bias on diagnostic misclassifications. Clinica Chimica Acta. 1997;260:189-206.
38. Bennett ST, Connelly DP, Eckfeldt JH. Assessment of split-sample proficiency testing for cholesterol by use of a computer simulation model. Clin Chem. 1991;37:497-503.
39. Branford S, Rudzki Z, Parkinson I, et al. Realtime quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926-2932.
40. Wang L, Knight K, Lucas C, Clark RE. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica. 2006;91:235-239.
41. Miller WG. Matrix effects in the measurement and standardization of lipids and lipoproteins. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. Washington, DC:AACC Press;1997:199-221.
42. Winn-Deen ES, Helton B, Van Atta R, et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin Chem. 2007;53:1593-1600.
43. Jobbagy Z, van Atta R, Murphy KM, Eshleman JR, Gocke CD. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J Mol Diagn. 2007;9: 220-227.